The Shareholders of Boehringer Ingelheim have appointed Dr Joachim Hasenmaier to Boehringer Ingelheim’s Board of Managing Directors. The 52-year old will take over responsibility for the new Consumer Health Care and Animal Health Board Division as of 1 October 2012. Prior to his appointment, Dr Hasenmaier was Regional Business Manager for Northern Europe and Canada. From 2001 to 2011, Hasenmaier was Divisional Head, Animal Health, at Boehringer Ingelheim. Before joining Boehringer Ingelheim, he held both management responsibilities in the field of animal health and worked as a consultant in Germany and internationally.
"Joachim Hasenmaier's appointment is the outcome of a long term human resource strategy. He has contributed to shaping the strategic and operational direction of our dynamically growing Animal Health business. Recognising the special focus of Animal Health and the Consumer Health Care business on the end-customer, it is meaningful to combine responsibilities in one Board Division," said Christian Boehringer, Chairman of the Shareholders' Committee of Boehringer Ingelheim.
The decision to enter the biosimilars business increases the strategic importance of Boehringer Ingelheim's Biopharmaceuticals business. There wil be a new Board DivisionBiopharmaceuticals and Operations on the Board of Managing Directors from 1 October 2012. It will be led byProfessor Wolfram Carius, who was previously responsible for the Board DivisionHuman Resources and Operations.
Now, Professor Andreas Barner will take over responsibilities for Human Resources simultaneously with his newly established function as Chairman (Vorsitzender) of the Board of Managing Directors. In the same function he also remains Board Member for Research & Development and Medicine.
The Finance Board Division is of particular significance in the current situation. For this reason, it has now been distinctly separated from the operational business divisions. Responsibility for the Finance Board Division will remain with Hubertus von Baumbach. In addition he heads the Family Administration of the Shareholder Family as Chairman of the Family Council.
In view of the rapidly changing pharmaceuticals environment and the preparation of the expected launches for Boehringer Ingelheim’s new therapeutic areas, the Prescription Medicines business is an important growth driver for the future. This Board Division will remain the responsibility of Engelbert Tjeenk-Willink.
Christian Boehringer: "The expansion of the Board of Managing Directors under the leadership of a Chairman (Vorsitzender) is a consequence of Boehringer Ingelheim's dynamic corporate development over the past 10 years, during which time company turnover has doubled and a further growth phase has now started in the company's 127-year history. We are well-positioned as an independent, innovation-driven pharmaceutical company for the challenges ahead on the global pharmaceutical market."
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.